| meta-analysis | Q815382 |
| systematic review | Q1504425 |
| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Jonathan Nguyen Van-Tam | Q41448199 |
| John Kenneth Baillie | Q42765467 | ||
| Paul Cleary | Q79919258 | ||
| P2093 | author name string | Wei Shen Lim | |
| Charles R Beck | |||
| Kevin D Rooney | |||
| John Mair-Jenkins | |||
| Maria Saavedra-Campos | |||
| Sophia Makki | |||
| Fu-Meng Khaw | |||
| Convalescent Plasma Study Group | |||
| P2860 | cites work | State of Knowledge and Data Gaps of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Humans | Q21128649 |
| SARS: systematic review of treatment effects | Q21144696 | ||
| Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement | Q21562278 | ||
| Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? | Q28260848 | ||
| Influenza vaccination for immunocompromised patients: systematic review and meta-analysis from a public health policy perspective | Q28740919 | ||
| Convalescent transfusion for pandemic influenza: preparing blood banks for a new plasma product? | Q30385673 | ||
| Hong Kong's experience on the use of extracorporeal membrane oxygenation for the treatment of influenza A (H1N1). | Q30397050 | ||
| Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. | Q30398715 | ||
| Clinical research during a public health emergency: a systematic review of severe pandemic influenza management. | Q30427085 | ||
| Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. | Q30427729 | ||
| Clinical characteristics of 26 human cases of highly pathogenic avian influenza A (H5N1) virus infection in China | Q33361942 | ||
| The management of coronavirus infections with particular reference to SARS. | Q34012358 | ||
| Advances in clinical diagnosis and treatment of severe acute respiratory syndrome | Q35151096 | ||
| Treatment of severe acute respiratory syndrome | Q36261771 | ||
| Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital | Q39615623 | ||
| Epidemiologic features, clinical diagnosis and therapy of first cluster of patients with severe acute respiratory syndrome in Beijing area | Q40553008 | ||
| Treatment of severe acute respiratory syndrome with convalescent plasma | Q40557957 | ||
| Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. | Q44950223 | ||
| Use of convalescent plasma therapy in SARS patients in Hong Kong | Q47875099 | ||
| Treatment of severe acute respiratory syndrome with convalescent plasma. | Q51660103 | ||
| [Clinical characteristics and therapeutic experience of case of severe highly pathogenic A/H5N1 avian influenza with bronchopleural fistula]. | Q54462491 | ||
| Severe acute respiratory syndrome (SARS) | Q73892875 | ||
| Successful treatment of avian influenza with convalescent plasma | Q79408048 | ||
| Treatment with convalescent plasma for influenza A (H5N1) infection | Q81391936 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International | Q24082749 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | severe acute respiratory syndrome | Q103177 |
| globulins | Q321710 | ||
| blood proteins | Q425056 | ||
| meta-analysis | Q815382 | ||
| systematic review | Q1504425 | ||
| RNA virus infectious disease | Q18967413 | ||
| hemic and immune systems | Q70202933 | ||
| fluids and secretions | Q71417785 | ||
| convalescent plasma | Q105209484 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 80-90 | |
| P577 | publication date | 2015-01-01 | |
| P1433 | published in | Journal of Infectious Diseases | Q4051141 |
| P1476 | title | The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis | |
| P478 | volume | 211 |
| Q30235281 | A Narrative Review of Influenza: A Seasonal and Pandemic Disease |
| Q39414987 | A clinical approach to the threat of emerging influenza viruses in the Asia-Pacific region |
| Q97566482 | A perspective on potential antibody-dependent enhancement of SARS-CoV-2 |
| Q40064548 | A review of candidate therapies for Middle East respiratory syndrome from a molecular perspective. |
| Q90575919 | A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence |
| Q30248209 | A review of treatment modalities for Middle East Respiratory Syndrome |
| Q50793231 | A roadmap for MERS-CoV research and product development: report from a World Health Organization consultation. |
| Q97422126 | A severe refractory COVID-19 patient responding to convalescent plasma; A case series |
| Q93257929 | Addressing the impact of the Coronavirus Disease (COVID-19) pandemic on hematopoietic cell transplantation: Learning networks as means for sharing best practices |
| Q96612547 | Adjunct Immunotherapies for the Management of Severely Ill COVID-19 Patients |
| Q94482870 | Advanced Pulmonary and Cardiac Support of COVID-19 Patients: Emerging Recommendations From ASAIO-A "Living Working Document" |
| Q93208817 | An invited commentary on: "Evidence Based Management Guideline for the COVID-19 Pandemic - Review article" |
| Q52320332 | Anti-Ebola Virus Antibody Levels in Convalescent Plasma and Viral Load after Plasma Infusion in Patients with Ebola Virus Disease. |
| Q96427923 | Anti-SARS-CoV-2 hyperimmune plasma workflow |
| Q93150027 | Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19 |
| Q90465411 | Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial |
| Q64120187 | Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection |
| Q99240439 | Antibody response to SARS-Co-V-2, diagnostic and therapeutic implications |
| Q99248437 | Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies |
| Q26781374 | Antiviral Treatment Guidelines for Middle East Respiratory Syndrome |
| Q94571714 | COVID-19 and Cancer: a Comprehensive Review |
| Q96647324 | COVID-19 and SARS Coronavirus 2: Antibodies for the Immediate Rescue and Recovery Phase |
| Q94594246 | COVID-19 and diabetes mellitus: An unholy interaction of two pandemics |
| Q92103339 | COVID-19 convalescent plasma transfusion |
| Q96230314 | COVID-19 infection: the China and Italy perspectives |
| Q94469834 | COVID-19: Immunology and treatment options |
| Q94476963 | COVID-19: Therapeutics and Their Toxicities |
| Q96030752 | COVID-19: Transmission, Prevention, and Potential Therapeutic Opportunities |
| Q91609262 | COVID-19: Yet another coronavirus challenge in transplantation |
| Q95625209 | COVID‐19: A review of therapeutics under investigation |
| Q57051585 | Case Report: Use of Plasma Exchange Followed by Convalescent Plasma Therapy in a Critically Ill Patient with Severe Fever and Thrombocytopenia Syndrome-Associated Encephalopathy: Cytokine/Chemokine Concentrations, Viral Loads, and Antibody Responses |
| Q104617821 | Clinical efficacy of convalescent plasma therapy on treating COVID-19 patients: Evidence from matched study and a meta-analysis |
| Q97086302 | Clinical, molecular, and epidemiological characterization of the SARS-CoV-2 virus and the Coronavirus Disease 2019 (COVID-19), a comprehensive literature review |
| Q97517131 | Convalescent Plasma Coupled With Medications for the Treatment of a Severe COVID-19 Patient: Drugs Analysis and Pharmaceutical Care Based on the Newly Established Guidelines for COVID-19 Remedy |
| Q91849630 | Convalescent Plasma Therapy for Corona Virus Disease 2019: a Long Way to Go but Worth Trying |
| Q99238028 | Convalescent Plasma: A Potential Life-Saving Therapy for Coronavirus Disease 2019 (COVID-19) |
| Q94488415 | Convalescent Plasma: Therapeutic Hope or Hopeless Strategy in the SARS-CoV-2 Pandemic |
| Q89954633 | Convalescent plasma as a potential therapy for COVID-19 |
| Q98953883 | Convalescent plasma from COVID 19 patients enhances intensive care unit survival rate. A preliminary report |
| Q94539926 | Convalescent plasma in Covid-19: Possible mechanisms of action |
| Q99551077 | Convalescent plasma therapy for COVID-19: a tried-and-true old strategy? |
| Q91919331 | Convalescent plasma therapy for persistent hepatitis E virus infection |
| Q98950575 | Convalescent plasma treatment for COVID-19: tempering expectations with the influenza experience |
| Q99551388 | Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study |
| Q26775412 | Convalescent plasma: new evidence for an old therapeutic tool? |
| Q87461314 | Coronavirus disease (COVID-19) and neonate: What neonatologist need to know |
| Q34513643 | Coronaviruses - drug discovery and therapeutic options. |
| Q83500389 | Coronaviruses: genome structure, replication, and pathogenesis |
| Q26764948 | Critically ill patients with Middle East respiratory syndrome coronavirus infection |
| Q93223160 | Current status of potential therapeutic candidates for the COVID-19 crisis |
| Q96607521 | Current treatment approaches for COVID-19 and the clinical value of transfusion-related technologies |
| Q36536012 | Design and analysis considerations in the Ebola_Tx trial evaluating convalescent plasma in the treatment of Ebola virus disease in Guinea during the 2014-2015 outbreak |
| Q53698876 | Detection, characterization, and enrollment of donors of Ebola convalescent plasma in Sierra Leone. |
| Q88600750 | EMERGING RESPIRATORY DISEASE - CORONAVIRUSES |
| Q44095775 | Ebola raises profile of blood-based therapy |
| Q30369241 | Ebola virus convalescent blood products: where we are now and where we may need to go. |
| Q35181810 | Ebola virus disease: the 'Black Swan' in West Africa |
| Q91611037 | Effectiveness of convalescent plasma therapy in severe COVID-19 patients |
| Q97093644 | Effects of the COVID-19 pandemic on supply and use of blood for transfusion |
| Q40252744 | Efficacy of antibody-based therapies against Middle East respiratory syndrome coronavirus (MERS-CoV) in common marmosets. |
| Q98163627 | Efficacy of convalescent plasma for the treatment of severe influenza |
| Q40044232 | Emerging Infections and Pertinent Infections Related to Travel for Patients with Primary Immunodeficiencies. |
| Q30459034 | Emerging novel and antimicrobial-resistant respiratory tract infections: new drug development and therapeutic options |
| Q30238587 | Epidemic and Emerging Coronaviruses (Severe Acute Respiratory Syndrome and Middle East Respiratory Syndrome). |
| Q91916624 | Epidemiological and clinical features of 125 Hospitalized Patients with COVID-19 in Fuyang, Anhui, China |
| Q39550507 | Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea |
| Q40079400 | Evaluation of convalescent whole blood for treating Ebola Virus Disease in Freetown, Sierra Leone. |
| Q30356651 | Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi Arabia. |
| Q30277992 | Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol |
| Q59356876 | Fully Human Immunoglobulin G From Transchromosomic Bovines Treats Nonhuman Primates Infected With Ebola Virus Makona Isolate |
| Q97535131 | Guidance for Healthcare Providers Managing COVID-19 in Rural and Underserved Areas |
| Q91829032 | Health-Related Quality of Life in Common Variable Immunodeficiency Italian Patients Switched to Remote Assistance During the COVID-19 Pandemic |
| Q38993000 | Human neutralizing antibodies against MERS coronavirus: implications for future immunotherapy |
| Q40787125 | Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoV in vivo |
| Q40159258 | IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study |
| Q30379199 | INSIGHT FLU005: An Anti-Influenza Virus Hyperimmune Intravenous Immunoglobulin Pilot Study. |
| Q47593481 | Identification of a Critical and Conformational Neutralizing Epitope in Human Adenovirus Type 4 Hexon |
| Q98464576 | Immune Response and COVID-19: A mirror image of Sepsis |
| Q40206880 | Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study |
| Q45324307 | Immune responses in influenza A virus and human coronavirus infections: an ongoing battle between the virus and host |
| Q39215653 | Immunotherapy for infectious diseases in haematological immunocompromise |
| Q91766310 | Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations |
| Q97419015 | Laboratory Tests for COVID-19: A Review of Peer-Reviewed Publications and Implications for Clinical UIse |
| Q44096329 | Large-scale convalescent blood and plasma transfusion therapy for Ebola virus disease |
| Q58595060 | MERS coronavirus outbreak: Implications for emerging viral infections |
| Q47738282 | MERS, SARS and other coronaviruses as causes of pneumonia. |
| Q33908067 | MERS-CoV Antibody Responses 1 Year after Symptom Onset, South Korea, 2015. |
| Q38809401 | MERS-CoV vaccine candidates in development: The current landscape |
| Q88600753 | MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS - MERS, MERS CoV |
| Q95313125 | Management and Treatment of COVID-19: The Chinese Experience |
| Q41163539 | Mapping the epitope of neutralizing monoclonal antibodies against human adenovirus type 3. |
| Q40590052 | Middle East Respiratory Syndrome Virus Pathogenesis |
| Q43280688 | Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: Current Therapeutic Options and Potential Targets for Novel Therapies |
| Q30274816 | Middle East Respiratory Syndrome. |
| Q40558082 | Middle East Respiratory Syndrome: Emergence of a Pathogenic Human Coronavirus |
| Q34468689 | Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease |
| Q40085786 | Middle East respiratory syndrome coronavirus: five years later. |
| Q37143501 | Middle East respiratory syndrome vaccines |
| Q51011540 | Middle East respiratory syndrome. |
| Q87748572 | Molecular immune pathogenesis and diagnosis of COVID-19 |
| Q97531501 | Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2 |
| Q96647455 | New Insights of Emerging SARS-CoV-2: Epidemiology, Etiology, Clinical Features, Clinical Treatment, and Prevention |
| Q92047788 | Novel 2019 Coronavirus Structure, Mechanism of Action, Antiviral drug promises and rule out against its treatment |
| Q35805087 | Novel citation-based search method for scientific literature: application to meta-analyses |
| Q66679577 | Overview of Current Therapeutics and Novel Candidates Against Influenza, Respiratory Syncytial Virus, and Middle East Respiratory Syndrome Coronavirus Infections |
| Q30368680 | Overview of the 3rd isirv-Antiviral Group Conference--advances in clinical management |
| Q39150633 | Passive immunotherapy for Middle East Respiratory Syndrome coronavirus infection with equine immunoglobulin or immunoglobulin fragments in a mouse model |
| Q35641110 | Passive immunotherapy with dromedary immune serum in an experimental animal model for Middle East respiratory syndrome coronavirus infection |
| Q40122905 | Pathogen-reduced Ebola virus convalescent plasma: first steps towards standardization of manufacturing and quality control including assessment of Ebola-specific neutralizing antibodies |
| Q93237085 | Pharmacotherapy in COVID-19; A narrative review for emergency providers |
| Q38699406 | Plasma therapy against infectious pathogens, as of yesterday, today and tomorrow. |
| Q95602961 | Position paper on the preparation of immune plasma to be used in the treatment of patients with COVID-19 |
| Q36864377 | Possible Transfusion-Related Acute Lung Injury Following Convalescent Plasma Transfusion in a Patient With Middle East Respiratory Syndrome |
| Q88182256 | Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review |
| Q96342888 | Potential drugs for the treatment of the novel coronavirus pneumonia (COVID-19) in China |
| Q97438796 | Potential effective treatment for COVID-19: systematic review and meta-analysis of the severe infectious disease with convalescent plasma therapy |
| Q37067663 | Preserved antiviral adaptive immunity following polyclonal antibody immunotherapy for severe murine influenza infection |
| Q36829831 | Prevalence of neutralizing antibodies to common respiratory viruses in intravenous immunoglobulin and in healthy donors in southern China |
| Q47210194 | Prevention and treatment of respiratory viral infections: Presentations on antivirals, traditional therapies and host-directed interventions at the 5th ISIRV Antiviral Group conference |
| Q56907500 | Prophylactic and therapeutic efficacy of mAb treatment against MERS-CoV in common marmosets |
| Q38776321 | Rapid generation of a human monoclonal antibody to combat Middle East respiratory syndrome |
| Q99203763 | Recent advances in use of fresh frozen plasma, cryoprecipitate, immunoglobulins, and clotting factors for transfusion support in patients with hematologic disease |
| Q89477874 | Recent discovery and development of inhibitors targeting coronaviruses |
| Q94489339 | Recommendations of the Working Groups from the Spanish Society of Intensive and Critical Care Medicine and Coronary Units (SEMICYUC) for the management of adult critically ill patients in the coronavirus disease (COVID-19) |
| Q40094147 | Recovery from the Middle East respiratory syndrome is associated with antibody and T-cell responses. |
| Q96647260 | Reducing the Fatality Rate of COVID-19 by Applying Clinical Insights From Immuno-Oncology and Lung Transplantation |
| Q40045378 | Repurposed Therapeutic Agents Targeting the Ebola Virus: A Systematic Review |
| Q94674303 | Research Progress of Drug Treatment in Novel Coronavirus Pneumonia |
| Q35763405 | Respiratory Infections in the U.S. Military: Recent Experience and Control |
| Q95644990 | Respiratory virus infections: Understanding COVID-19 |
| Q95627597 | Review of trials currently testing treatment and prevention of COVID-19 |
| Q94547370 | Role of adjunctive treatment strategies in COVID-19 and a review of international and national clinical guidelines |
| Q30249325 | SARS and MERS: recent insights into emerging coronaviruses |
| Q97523390 | SARS-CoV-2 proteome microarray for global profiling of COVID-19 specific IgG and IgM responses |
| Q98944371 | SARS-CoV-2 serology and virology trends in donors and recipients of convalescent plasma |
| Q99553547 | Screening for SARS-CoV-2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program |
| Q30252378 | Serotherapy for patients with severe influenza |
| Q93239439 | Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Emergence, History, Basic and Clinical Aspects |
| Q96647383 | Severe COVID-19: A Review of Recent Progress With a Look Toward the Future |
| Q95602292 | Successful treatment of a centenarian with coronavirus disease 2019 (COVID-19) using convalescent plasma |
| Q90735399 | Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19) |
| Q90722842 | Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19) |
| Q35989719 | Swift antibodies to counter emerging viruses |
| Q39319893 | Tackling influenza with broadly neutralizing antibodies |
| Q98288123 | The 2019-2020 Novel Coronavirus (Severe Acute Respiratory Syndrome Coronavirus 2) Pandemic: A Joint American College of Academic International Medicine-World Academic Council of Emergency Medicine Multidisciplinary COVID-19 Working Group Consensus P |
| Q94545219 | The Current and Future State of Vaccines, Antivirals and Gene Therapies Against Emerging Coronaviruses |
| Q97545650 | The Emerging Role of Convalescent Plasma in the Treatment of COVID-19 |
| Q99237794 | The Impact of Pre-existing Comorbidities and Therapeutic Interventions on COVID-19 |
| Q34489055 | The Use of Ebola Convalescent Plasma to Treat Ebola Virus Disease in Resource-Constrained Settings: A Perspective From the Field |
| Q90296531 | The convalescent sera option for containing COVID-19 |
| Q100464001 | The efficacy assessment of convalescent plasma therapy for COVID-19 patients: a multi-center case series |
| Q45030988 | The search for therapeutic options for Middle East Respiratory Syndrome (MERS). |
| Q91727876 | The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic and Transfusion Medicine: reflections from Italy |
| Q99585291 | Therapeutic Options in the Treatment of SARS-CoV-2 in the Pregnant Patient |
| Q33421511 | Therapeutic effect of post-exposure treatment with antiserum on severe fever with thrombocytopenia syndrome (SFTS) in a mouse model of SFTS virus infection. |
| Q94942446 | Towards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, and corticosteroids |
| Q94451230 | Treatment for emerging viruses: Convalescent plasma and COVID-19 |
| Q90702138 | Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma |
| Q96026495 | Treatment of COVID-19 Patients with Convalescent Plasma |
| Q98460873 | Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks |
| Q90364890 | Treatment of COVID-19: old tricks for new challenges |
| Q36555622 | Treatment strategies for Middle East respiratory syndrome coronavirus |
| Q40124612 | Treatment-donation-stockpile dynamics in ebola convalescent blood transfusion therapy |
| Q94657383 | Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial |
| Q38587113 | Update in Viral Infections 2014. |
| Q31119325 | Update on Human Rhinovirus and Coronavirus Infections |
| Q39034541 | Update on therapeutic options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV). |
| Q91849623 | Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea |
| Q42559493 | Use of Plasma Therapy for Severe Fever with Thrombocytopenia Syndrome Encephalopathy |
| Q30238976 | Use of convalescent plasma in Ebola virus infection |
| Q95265304 | Why should we use convalescent plasma for COVID-19? |
| Q99629523 | [COVID-19, management, therapeutic and vaccine approaches] |
| Q94589568 | [Effect of heat inactivation of blood samples on the efficacy of three detection methods of SARS-CoV-2 antibodies] |
Search more.